10-Minute Prostate Specific Antigen Test Provides Early Prostate Cancer Warning

4 million new cases diagnosed and 375,000 deaths reported worldwide in 2020. Alarmingly, a new case is diagnosed every two minutes. While significant progress has been made in early detection and research, prostate cancer remains a major public health concern. Elevated levels of prostate-specific antigen (PSA), a substance produced by the prostate and released in trace amounts into the bloodstream, may indicate potential prostate disease. Now, a new test designed to detect elevated PSA levels from a finger-prick blood sample could serve as an early warning sign for prostate cancer.

Biomerica’s (Irvine, CA, USA) Fortel PSA Screening Test is a simple, user-friendly diagnostic tool that provides accurate results within just 10 minutes using a finger-prick blood sample. By measuring elevated PSA levels, a known early indicator of prostate disease, the test helps with the early detection of prostate cancer and other related conditions. This accessible and rapid method aims to improve proactive health management, ease the burden on healthcare systems, and enhance patient outcomes. The Fortel PSA test has shown exceptional performance in rigorous evaluations, with a study reporting 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods. Further studies have validated the test’s effectiveness, showing 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy. These promising results highlight the Fortel PSA test as a reliable and efficient tool for early detection.